BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 22847364)

  • 1. Villous papillary thyroid carcinoma: a variant associated with marfan syndrome.
    Winer DA; Winer S; Rotstein L; Asa SL; Mete O
    Endocr Pathol; 2012 Dec; 23(4):254-9. PubMed ID: 22847364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rewiring of the apoptotic TGF-β-SMAD/NFκB pathway through an oncogenic function of p27 in human papillary thyroid cancer.
    Garcia-Rendueles AR; Rodrigues JS; Garcia-Rendueles ME; Suarez-Fariña M; Perez-Romero S; Barreiro F; Bernabeu I; Rodriguez-Garcia J; Fugazzola L; Sakai T; Liu F; Cameselle-Teijeiro J; Bravo SB; Alvarez CV
    Oncogene; 2017 Feb; 36(5):652-666. PubMed ID: 27452523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TGF-beta/Smad pathway and BRAF mutation play different roles in circumscribed and infiltrative papillary thyroid carcinoma.
    Eloy C; Santos J; Cameselle-Teijeiro J; Soares P; Sobrinho-Simões M
    Virchows Arch; 2012 Jun; 460(6):587-600. PubMed ID: 22527019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF (V600E) associates with cytoplasmatic localization of p27kip1 and higher cytokeratin 19 expression in papillary thyroid carcinoma.
    Guerra A; Marotta V; Deandrea M; Motta M; Limone PP; Caleo A; Zeppa P; Esposito S; Fulciniti F; Vitale M
    Endocrine; 2013 Aug; 44(1):165-71. PubMed ID: 23203004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic value of HBME-1, CD56, Galectin-3 and Cytokeratin-19 in papillary thyroid carcinomas and thyroid tumors of uncertain malignant potential.
    Nechifor-Boilă A; Cătană R; Loghin A; Radu TG; Borda A
    Rom J Morphol Embryol; 2014; 55(1):49-56. PubMed ID: 24715165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absence of BRAF V600E in non-infiltrative, non-invasive follicular variant of papillary thyroid carcinoma.
    Howitt BE; Paulson VA; Barletta JA
    Histopathology; 2015 Oct; 67(4):579-82. PubMed ID: 25736029
    [No Abstract]   [Full Text] [Related]  

  • 7. Up-regulation of urinary-type plasminogen activator correlates with high-risk papillary thyroid carcinoma with BRAF(V600E) mutation and its possible molecular mechanism.
    Wakasa T; Li Y; Bai Y; Liu Z; Ozaki T; Mori I; Miyauchi A; Kakudo K; Nakamura M
    Pathol Res Pract; 2014 Nov; 210(11):733-8. PubMed ID: 25085839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience.
    Gouveia C; Can NT; Bostrom A; Grenert JP; van Zante A; Orloff LA
    JAMA Otolaryngol Head Neck Surg; 2013 Nov; 139(11):1164-70. PubMed ID: 24030686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclin D1 in well differentiated thyroid tumour of uncertain malignant potential.
    Lamba Saini M; Weynand B; Rahier J; Mourad M; Hamoir M; Marbaix E
    Diagn Pathol; 2015 Apr; 10():32. PubMed ID: 25907675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling.
    Knauf JA; Sartor MA; Medvedovic M; Lundsmith E; Ryder M; Salzano M; Nikiforov YE; Giordano TJ; Ghossein RA; Fagin JA
    Oncogene; 2011 Jul; 30(28):3153-62. PubMed ID: 21383698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel BRAF and KRAS Mutations in Papillary Thyroid Carcinoma Arising in Struma Ovarii.
    Tan A; Stewart CJ; Garrett KL; Rye M; Cohen PA
    Endocr Pathol; 2015 Dec; 26(4):296-301. PubMed ID: 26362194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The expression of monocarboxylate transporters in thyroid carcinoma can be associated with the morphological features of BRAF
    Rossi ED; Bizzarro T; Granja S; Martini M; Capodimonti S; Luca E; Fadda G; Lombardi CP; Pontecorvi A; Larocca LM; Baltazar F; Schmitt F
    Endocrine; 2017 May; 56(2):379-387. PubMed ID: 27484771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cribriform-morular variant of papillary thyroid carcinoma in an 8-year-old girl: a case report with immunohistochemical and molecular testing.
    Rossi ED; Revelli L; Martini M; Taddei A; Pintus C; Panunzi C; Fadda G
    Int J Surg Pathol; 2012 Dec; 20(6):629-32. PubMed ID: 22494995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic prediction of BRAF(V600E) and its relationship with sodium iodide symporter in classic variant of papillary thyroid carcinomas.
    Gao WL; Wie LL; Chao YG; Wie L; Song TL
    Clin Lab; 2012; 58(9-10):919-26. PubMed ID: 23163107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Caveolin-1 expression in papillary thyroid carcinoma: correlation with clinicopathological parameters and BRAF mutation status.
    Paskaš S; Janković J; Marečko I; Išić Denčić T; Tatić S; Cvejić D; Savin S
    Otolaryngol Head Neck Surg; 2014 Feb; 150(2):201-9. PubMed ID: 24255086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathologic correlations of the BRAFV600E mutation, BRAF V600E immunohistochemistry, and BRAF RNA in situ hybridization in papillary thyroid carcinoma.
    Jung YY; Yoo JH; Park ES; Kim MK; Lee TJ; Cho BY; Chung YJ; Kang KH; Ahn HY; Kim HS
    Pathol Res Pract; 2015 Feb; 211(2):162-70. PubMed ID: 25468810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
    Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
    Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The correlation of sodium iodide symporter and BRAF(V600E) mutation in classical variant papillary thyroid carcinoma.
    Yazgan A; Yıldırım N; Gözalan A; Gümüştaş S; Kılıçarslan A; Balci S; Aydın C; Ersoy R; Cakir B; Güler G
    Ann Diagn Pathol; 2016 Jun; 22():58-62. PubMed ID: 27180062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [BRAF-STATUS OF PAPILLARY THYROID CARCINOMAS AND STRATEGY OF SURGICAL TREATMENT].
    Tarashchenko YN; Kovalenko AE; Bolgov MY; Guda BB; Shelkovoy EA; Nekrasov KA; Mankovskaya S; Kashuba VI
    Klin Khir; 2015 Jun; (6):49-54. PubMed ID: 26521469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of Papillary Thyroid Carcinoma into Tall Cell Variant and TENIS Syndrome.
    Chakraborty A; Kane SV; Pawer Y; Basu S
    J Nucl Med Technol; 2016 Dec; 44(4):255-258. PubMed ID: 27834723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.